Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease
Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease
复制标题
DOI：
10.1016/j.jaci.2014.07.031
复制
发表时间：
2015-01-01
影响因子：
14.2
通讯作者：
Laidlaw, Tanya M.
中科院分区：
文献类型：
--
作者：
Cahill, Katherine N.;Bensko, Jillian C.;Laidlaw, Tanya M.
背景：阿司匹林脱敏后大剂量阿司匹林治疗是阿司匹林加重呼吸系统疾病（AERD）患者的常规治疗方法。对于半胱氨酸白三烯以外的介质对阿司匹林反应的作用以及对大剂量阿司匹林治疗的疗效所知甚少。目的：我们研究耐受和不耐受阿司匹林脱敏的AERD患者以及成功接受大剂量阿司匹林治疗的AERD患者尿类20蛋白代谢物水平和血嗜酸性粒细胞计数的差异。方法：29例AERD患者分为耐受阿司匹林脱敏组（I组）和不耐受阿司匹林脱敏组（II组）。在基线、阿司匹林反应期间和大剂量阿司匹林治疗期间，分析尿液的类二十烷酸代谢物。在基线和阿司匹林治疗期间分析血液细胞差异。结果：基础前列腺素D-2代谢物（PGD-M）； 13.6 +/- 2.7 vs 7.0 +/- 0.8 pmol/mg肌酐[Cr]， P
Background: Aspirin desensitization followed by high-dose aspirin therapy is routinely performed for patients with aspirin-exacerbated respiratory disease (AERD). Little is known about the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose aspirin therapy.Objective: We investigated differences in urinary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolerate and those who fail aspirin desensitization and also in patients with AERD who were successfully treated with high-dose aspirin therapy.Methods: Twenty-nine patients with AERD were stratified into those who tolerated aspirin desensitization (group I) and those who did not (group II). Urine was analyzed for eicosanoid metabolites at baseline, during aspirin reactions, and during high-dose aspirin therapy. Blood was analyzed for cell differentials at baseline and during aspirin therapy.Results: Basal prostaglandin D-2 metabolite (PGD-M; 13.6 +/- 2.7 vs 7.0 +/- 0.8 pmol/mg creatinine [Cr], P